Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT327 plus etoposide/carboplatin versus atezolizumab plus etoposide/carboplatin in untreated extensive-stage small-cell lung cancer
NL-OMON61053Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pumitamig in small cell lung cancer (SCLC) (2 arms), sponsored by BioNTech SE. Primary endpoint: Overall survival. Started Oct 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON61053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61053.